IPN Ipsen S.A.

Ipsen (ENXTPA:IPN) has refreshed its governance, with the board appointing Mariette Finet as Director and member of the Board Portfolio Committee following Michèle Ollier’s resignation earlier in the summer. Ipsen’s share price has softened in the short term, with a 1-month share price return down 10.18% and a 7-day move lower by 4.30%. The stock is still up 28.42% year to date and has delivered a 35.14% total shareholder return over the past year, suggesting longer term momentum remains...

All the chairs of Europe’s big pharma companies have written a public letter asserting that a shift in strategy is needed to close the gap to international rivals.

LONDON, Sept 22 (Reuters) - European drugmakers called for beefed-up government spending on medicines, faster trials and IP protections as they sounded warnings ‌on Tuesday that the continent's pharmaceutical industry risks losing out to the ‌United States and China. Cash-strapped European governments have been under pressure for some time from lobby groups ​and drugmakers to rethink how they attract, nurture, value and pay for innovative medicines to avoid falling behind in an increasingly com

Stock fell sharply after the U.S. Food and Drug Administration approved a generic competitor to its flagship Somatuline hormone drug earlier than expected.

The Food and Drug Administration (FDA) cleared a 120-milligram prefilled syringe that copies Ipsen’s Somatuline Depot, a long-acting under-the-skin injection.

Mirum and Incyte are now awaiting the FDA’s decision on zilurgisertib, a once-a-day pill for an ultra-rare bone disease.

The French drugmaker is considering building a U.S. production site, joining other European companies looking across the pond when planning new investments.